178 results
Page 6 of 9
6-K
EX-99.1
cmb3ccshgaki9hlcp
18 Nov 20
Enlivex Reports Positive Two-Year Clinical Outcome For A Hospitalized Patient with Erosive Osteoarthritis Treated with Allocetra
8:02am
6-K
EX-99.1
7ed7l8z3 nnp32grnwi
17 Nov 20
Enlivex Appoints Former ArQule, Inc. Executive Dr. Brian Schwartz to the Company’s Board of Directors
8:18am
6-K
EX-99.1
2efn0
12 Nov 20
Enlivex to Present Schedule for Sepsis, COVID-19 and Solid Cancer Programs at H.C. Wainwright’s 6th Annual Israel Conference
8:01am
6-K
EX-99.1
qce3cd7
3 Nov 20
Current report (foreign)
9:14am
6-K
EX-99.2
4jm4jv1
30 Oct 20
Condensed Consolidated Financial Statements
4:30pm
6-K
EX-99.1
fg9dm
27 Oct 20
Report of Foreign Private Issuer
8:03am
6-K
EX-99.1
hs4rj o45v
22 Oct 20
Enlivex Reports Dosing of First Two Patients in Phase II Clinical Trial Evaluating Allocetra in Severe and Critical COVID-19 Patients
8:49am
6-K
EX-10.1
q5va7ncallc0w552jb15
22 Oct 20
Report of Foreign Private Issuer
8:47am
424B5
v1bl4 f3zq01
22 Oct 20
Prospectus supplement for primary offering
8:45am
6-K
EX-99.1
lg63r e2vlepml3r
13 Oct 20
Report of Foreign Private Issuer
9:30am
6-K/A
EX-99.2
tni8a0llf6mb
13 Oct 20
Condensed Consolidated Financial Statements
9:16am
6-K
EX-99.1
crxrtnw4f8dg4q7y
1 Oct 20
Enlivex Reports Positive Allocetra Trial Results in COVID-19 Patients in Severe/Critical Condition
6:06am
6-K
EX-99.1
hm1vmjfg
16 Sep 20
Enlivex Announces Allowance of New Chinese Patent Covering Allocetra Immunotherapy
8:02am
6-K
EX-99.1
wf8i9i
25 Aug 20
Enlivex Announces Allowance of New U.S. Patent Covering Allocetra Immunotherapy
8:02am
6-K
EX-99.2
ztuq3ih7h2x6qa9
14 Aug 20
Condensed Consolidated Financial Statements
4:23pm
6-K
EX-99.1
bfjmsv9711s31oawb
10 Aug 20
Enlivex Announces Dosing of First Patient in Clinical Trial of Allocetra in COVID-19 Patients with Severe Illness Respiratory Failure
8:02am
6-K
EX-99.1
1pqpk8yn uhlp
18 Jun 20
Enlivex Announces Allowance of New Japanese Patent Application Covering ALLOCETRA Immunotherapy
8:32am
6-K
EX-99.1
5k3e2uo9y7uzpyhy8a4
28 May 20
Report of Foreign Private Issuer
9:25am
6-K
EX-99.1
17g095xxzv500opmmaw
19 May 20
Annual and Extraordinary General Meeting of Shareholders
8:04am
6-K
EX-99.2
5em6a
18 May 20
Condensed Consolidated Financial Statements
4:30pm